GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Jie Xiang,Liyan Qin,Jinling Zhong,Ning Xia,Yuzhen Liang
DOI: https://doi.org/10.2147/DMSO.S425642
2023-08-16
Abstract:Jie Xiang, 1 Liyan Qin, 2 Jinling Zhong, 3 Ning Xia, 2 Yuzhen Liang 3 1 Department of Clinical Nutrition, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China; 2 Department of Geriatric Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China; 3 Department of Endocrinology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China Correspondence: Yuzhen Liang, Department of Endocrinology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China, Email Ning Xia, Department of Geriatric Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China, Email Background: Obesity is related to the loss of skeletal muscle mass and function (sarcopenia). The co-existence of obesity and sarcopenia is called sarcopenic obesity (SO). Glucagon like peptide-1 receptor agonists (GLP-1RA) are widely used in the treatment of diabetes and obesity. However, the protective effects of GLP-1RA on skeletal muscle in obesity and SO are not clear. This study investigated the effects of GLP-1RA liraglutide and semaglutide on obesity-induced muscle atrophy and explored the underlying mechanisms. Methods: Thirty-six male C57BL/6J mice were randomly divided into two groups and fed a regular diet and a high-fat diet for 18 weeks, respectively. After establishing an obesity model, mice were further divided into six groups: control group, liraglutide (LIRA) group, semaglutide (SEMA) group, high-fat diet (HFD) group, HFD + LIRA group, HFD + SEMA group, and subcutaneous injection for 4 weeks. The body weight, muscle mass, muscle strength, glycolipid metabolism, muscle atrophy markers, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed. C2C12 myotube cells treated with palmitic acid (PA) were divided into four groups: control group, PA group, PA + LIRA group, PA + SEMA group. The changes in glucose uptake, myotube diameter, lipid droplet infiltration, markers of muscle atrophy, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed, and the changes in related indicators were observed after the addition of SIRT1 inhibitor EX527. Results: Liraglutide and semaglutide reduced HFD-induced body weight gain, excessive lipid accumulation and improved muscle atrophy. Liraglutide and semaglutide eliminated the increase of muscle atrophy markers in skeletal muscle and C2C12 myotubes. Liraglutide and semaglutide restored impaired glucose tolerance and insulin resistance. However, these beneficial effects were attenuated by inhibiting SIRT1 expression. Conclusion: Liraglutide and semaglutide protects skeletal muscle against obesity-induced muscle atrophy via the SIRT1 pathway. Keywords: liraglutide, semaglutide, muscle atrophy, obesity, insulin resistance, SIRT1 Obesity (defined as BMI ≥ 30 kg/m 2 ) is a chronic disease characterized by abnormal body fat or over-accumulation, which affects more than 1 billion people worldwide. 1 Due to a sedentary lifestyle, adipose tissue disorders, comorbidities (acute and chronic diseases) and metabolic changes during aging, loss of skeletal muscle mass and function (sarcopenia) is common in obese patients. 2 The decrease in muscle mass/function coexists with an increase in fat mass, is referred to as sarcopenic obesity (SO). 3 Compared to obesity alone, SO is associated with an increased risk of adverse health consequences, such as disability, cardiovascular metabolic diseases, other comorbidities and mortality. 4 The deposition of ectopic fat caused by obesity can lead to biological dysfunction of skeletal muscles, including inflammation, insulin resistance (IR) and oxidative stress. 5 These changes further exacerbate the loss of skeletal muscles and physical dysfunction. 6 Therefore, a deep understanding of the potential mechanisms of SO is crucial for its accurate diagnosis, effective prevention and treatment. Currently, the main treatment for SO is lifestyle intervention, including calorie restriction and physical activity. 7 However, there are still some limitations in the treatment of SO. 8 Therefore, determining the therapeutic targets of SO has attracted widespread attention. Glucagon like peptide-1 (GLP-1) is a hormone secreted by intestinal L cells, which reacts to nutrients and plays a glucose dependent insulin promoting role in pancreatic islet cells. 9 In addition, GLP-1 has multiple effects on various organ systems. Especially the decrease in appetite and food intake, leading to weight loss wit -Abstract Truncated-
endocrinology & metabolism